FDA Approves VIVUS (VVUS) Weight-Management Drug Qsymia
Tweet Send to a Friend
Get Alerts VVUS Hot Sheet
Trade VVUS Now!
The FDA approved VIVUS, Inc.'s (Nasdaq: VVUS) weight-loss drug Qsymia (Qnexa) as added reduced-calorie diet pill, according to Bloomberg headlines.
VIVUS will be required to conduct 10 postmarketing requirements.
Shares are currently halted.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
VIVUS will be required to conduct 10 postmarketing requirements.
Shares are currently halted.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- VIVUS, Inc. (VVUS) to Make Several Scientific Presentations in May
- St. Jude Medical (STJ) Issues Encouraging Update for EnligHTN™ Multi-Electrode Renal Denervation System Following One Year
- Amazon (AMZN) Expands Kindle Fire HD into 170 Additional Markets
Create E-mail Alert Related Categories
Corporate News, FDA, Hot Corp. News, Hot FDA News, Hot List
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
